Cargando…
1331. High direct costs caused by Cryptococcal meningitis treated with Amphotericin B deoxycholate in a public hospital in Lima, Peru. 2021-2022
BACKGROUND: Cryptococcal meningitis (CM) is a severe disease caused by a ubiquitous fungus that affects both immunocompetent and immunosuppressed people. The treatment of choice includes liposomal amphotericin plus flucytosine; however, in Peru, both medications are not available. Hence, in Peru, CM...
Autores principales: | Vilcarromero, Stalin, Luque, Arturo, Luarte, Norka, Mateo-Pacora, Jimmy, Mendo, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678460/ http://dx.doi.org/10.1093/ofid/ofad500.1169 |
Ejemplares similares
-
Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis
por: Bicanic, Tihana, et al.
Publicado: (2015) -
Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018) -
Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa
por: Meiring, Susan, et al.
Publicado: (2016) -
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
por: Jarvis, Joseph N, et al.
Publicado: (2022) -
Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China
por: Zhao, Ting, et al.
Publicado: (2022)